|
Liponex Inc. today updated the development status of its lead product, CRD5. The compound has been in development for the treatment of dyslipidemia and heart disease
OTTAWA, Canada | December 13, 2007 | Liponex Inc. (TSX: LPX), a biopharmaceutical company specializing in developing advanced products related to High Density Lipoprotein (HDL), often called “good cholesterol,” today updated the development status of its lead product, CRD5. The compound has been in development for the treatment of dyslipidemia and heart disease.
Liponex has been working to develop an appropriate animal model to predict CRD5’s effects in humans, a task which has very little historical precedence with HDL drugs. Studies with the new enteric coated formulation of CRD5 in mini-pigs have been ongoing since July 2007 and to date no significant effects have been observed for CRD5 relative to control in this model. Consequently we have discontinued these trials.
The Board and management will assess the next steps for the CRD5 program in light of these results and, in parallel, continue efforts around strategic options to leverage the company’s assets and resources. There are a number of alternatives currently under consideration by the Board.
About Liponex
Liponex is a biopharmaceutical company specializing in developing products related to High Density Lipoprotein (HDL), often called "good cholesterol." Its drug candidates relate to the various roles of HDL as a transport vehicle, including removing excess cholesterol from the body, delivering molecules to cells and removing unwanted materials from the body. Liponex is listed on the TSX under the ticker "LPX". For more information on Liponex, visit www.liponex.ca.
Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements of “belief” or “expectation” with respect to the success of enteric coating, the development of animal models to predict HDL drug effects, the undertaking of future clinical trials for CRD5 as well as CRD5’s efficacy in raising HDL levels, are based primarily upon results derived to date from the Company’s pre-clinical research and development and its results from completed Phase I and Phase I/II clinical trials. While the Company believes that it has reasonable scientific basis upon which to make such statements, it is not possible to predict whether a new therapeutic agent will be prove to be safe and/or effective in humans. The Company cannot guarantee that it actually will achieve the plans, intentions or expectation and undue reliance should not be placed on those forward-looking statements. The Company does not expect to update forward-looking statements continually as conditions change. Investors are referred to the full discussion of risk factors associated with the Company's business contained in the Company's periodic regulatory filings, which can be found in the SEDAR database at www.sedar.com.
SOURCE: Liponex |
